Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Inflammatory Breast Neoplasms × Epirubicin × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 15 Triple Negative Breast Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 2 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Non-Muscle Invasive Bladder Neoplasms 1 Nasopharyngeal Carcinoma 1 Lymphoma, T-Cell, Peripheral 1 Inflammatory Breast Neoplasms 1 HR+/HER2- Breast Cancer 1 Epstein-Barr Virus Infections 1 Congenital Abnormalities 1 Carcinoma, Adenoid Cystic 1 CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1

Interventions

Paclitaxel 6 Cyclophosphamide 5 Doxorubicin 4 pembrolizumab 3 eribulin 3 Taxes 3 pertuzumab 2 Trastuzumab 2 Specimen Handling 2 Radiotherapy 2 trastuzumab biosimilar HLX02 1 ruxolitinib 1 romidepsin 1 onvansertib 1 olaparib 1 neratinib 1 grapiprant 1 cobimetinib 1 caficrestat 1 atezolizumab 1 X-Rays 1 Therapeutics 1 Tamoxifen 1 Surgical Procedures, Operative 1 Radiation 1 Peripheral Blood Stem Cell Transplantation 1 Panitumumab 1 Palliative Care 1 PF-05280014 1 Ontruzant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03515798 2025-09-12

PELICAN

Institut Paoli-Calmettes

Phase 2 Active not recruiting

Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡